Veracyte Raises $55.1M in Public Offering
The company said proceeds will be used for working capital, and may also be used to acquire or invest in complementary businesses or technologies.
Veracyte Prices $51.3M Public Offering
Veracyte will offer 5 million shares at $10.25 per share. It has granted underwriters an option to purchase an additional 750,000 shares.
Despite an initial focus on cardiovascular disease, Miragen has moved programs in hematological cancer and fibrosis to the front of its pipeline.
Edinburgh Molecular Imaging Receives $6.5M Investment
NEW YORK (GenomeWeb News) – Molecular imaging firm Edinburgh Molecular Imaging has received £4 million ($6.5 million) in a Series A investment, life science capital venture fund Epidarex Capital announced today.
Regulus Therapeutics remains on track to filing an investigational new drug application for its microRNA-targeting hepatitis C treatment RG-101 next year, with a second candidate — likely for fibrosis or cancer — to be added to the company's formal pipeline before the end of 2013
Jun 6, 2013
Nov 29, 2012
Jun 18, 2012
KineMed, GSK Partner on Biomarker Discovery Deal
Mar 13, 2012
Epistem, GSK Partner to Better Understand Fibrosis
Jun 24, 2010